logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12319669 B1

PDFFull Text
Date of Patent:
Jun. 03, 2025

Filed:

Sep. 28, 2023

Glp-1 receptor agonists and uses thereof

Applicant:

Pfizer Inc., New York, NY (US);

Inventors:

Gary Erik Aspnes, Biberach an der Riss, DE;

Scott W. Bagley, Voluntown, CT (US);

John M. Curto, Mystic, CT (US);

Matthew S. Dowling, Old Lyme, CT (US);

David Edmonds, Basel, CH;

Mark E. Flanagan, Gales Ferry, CT (US);

Kentaro Futatsugi, Sharon, MA (US);

David A. Griffith, Sudbury, MA (US);

Kim Huard, Berkeley, CA (US);

Gajendra Ingle, New Haven, CT (US);

Wenhua Jiao, Salem, CT (US);

Chris Limberakis, Pawcatuck, CT (US);

Alan M. Mathiowetz, Waltham, MA (US);

David W. Piotrowski, Waterford, CT (US);

Roger B. Ruggeri, Waterford, CT (US);

Assignee:

Pfizer Inc., New York, NY (US);

Attorney:

Feng Shao

Primary Examiner:

Samantha L Shterengarts

Int. Cl.
CPC ...
A61K 31/496 (2006.01); A61K 31/4545 (2006.01); A61P 1/00 (2006.01); A61P 1/16 (2006.01); A61P 3/00 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61P 9/10 (2006.01); A61P 13/12 (2006.01); A61P 15/00 (2006.01); A61P 15/10 (2006.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 19/06 (2006.01); A61P 25/02 (2006.01); A61P 25/16 (2006.01); A61P 25/18 (2006.01); A61P 25/28 (2006.01); A61P 25/30 (2006.01); A61P 43/00 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61P 1/00 (2018.01); A61P 1/16 (2018.01); A61P 3/00 (2018.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); A61P 9/10 (2018.01); A61P 13/12 (2018.01); A61P 15/00 (2018.01); A61P 15/10 (2018.01); A61P 17/06 (2018.01); A61P 19/02 (2018.01); A61P 19/06 (2018.01); A61P 25/02 (2018.01); A61P 25/16 (2018.01); A61P 25/18 (2018.01); A61P 25/28 (2018.01); A61P 25/30 (2018.01); A61P 43/00 (2018.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01);
Abstract

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

Find Patent Forward Citations

Loading…